RxDoctor Payments Data

Kareen Simpson, MD

Nephrology · Chicago, ILNPI 1780663963

Payments from drug & device makers

$1,242in general payments, 2019–2025

Across 40 payments — averaging $31.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$295
  • Amgen$206
  • Akebia Therapeutics Inc$164
  • Fresenius USA Marketing, Inc.$157
  • Ardelyx, Inc.$120
  • Nxstage Medical, Inc.$79
  • plus $221 from 6 others

What the payments were for

  • Food & beverage$1,242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,242 in reported general payments places this provider in the 55th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$288,999
Medicare patients
272
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide46$142,309
Sevelamer Carbonate262$46,875
FarxigaDapagliflozin Propanediol29$25,913
LokelmaSodium Zirconium Cyclosilicate29$18,508
AuryxiaFerric Citrate13$17,756
Lanthanum Carbonate13$12,010
VeltassaPatiromer Calcium Sorbitex11$10,548
SpsSodium Polystyrene Sulfon/Sorb11$9,674
Cinacalcet Hcl16$7,382
EliquisApixaban11$6,333
Paricalcitol11$1,452
Nifedipine ErNifedipine54$1,412
Hydralazine Hcl79$1,205
Carvedilol63$675
Calcium Acetate16$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$157$142,30946 claims
AstraZenecaFarxiga, Lokelma$295$44,42258 claims
Akebia Therapeutics IncAuryxia$164$17,75613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →